Gene Technologies for Medicines: Public and Business Demands
- Authors: Morozov D.V.1, Ivanov R.A.1, Gershovich P.M.1, Pestova N.E.1, Petrova M.V.1
-
Affiliations:
- BIOCAD Biotechnological Company, poselok Strel’na
- Issue: Vol 89, No 2 (2019)
- Pages: 167-170
- Section: Scientific Session of the General Meeting of the Russian Academy of Sciences
- URL: https://journals.rcsi.science/1019-3316/article/view/179251
- DOI: https://doi.org/10.1134/S1019331619020138
- ID: 179251
Cite item
Abstract
At the present time, gene technologies play a key part in the development of new approaches to the diagnostics and therapy of diseases. Russian scientists have already successfully introduced efficient preparations based on multiclonal antibodies into practice and have advanced developments in the fields of CAR-T therapy and gene-therapy preparations on the basis of recombinant adenoassociated viruses. Some gene diagnostic tools, which essentially improve the efficiency of medical care due to the personalized approach to the therapy of diseases, are also put into practice. The successful introduction of innovative technologies and contemporary methods of diagnostics and therapy is impossible without cooperation between academic science and business. The companies providing the conditions for cooperation with academic science and engagement of specialists of different profiles have hastened the mass introduction of gene technologies and, therefore, the defeat over many earlier incurable socially significant diseases.
About the authors
D. V. Morozov
BIOCAD Biotechnological Company, poselok Strel’na
Author for correspondence.
Email: morozov@biocad.ru
Russian Federation, St. Petersburg, 198515
R. A. Ivanov
BIOCAD Biotechnological Company, poselok Strel’na
Author for correspondence.
Email: ivanov@biocad.ru
Russian Federation, St. Petersburg, 198515
P. M. Gershovich
BIOCAD Biotechnological Company, poselok Strel’na
Author for correspondence.
Email: gershovich@biocad.ru
Russian Federation, St. Petersburg, 198515
N. E. Pestova
BIOCAD Biotechnological Company, poselok Strel’na
Author for correspondence.
Email: pestova@biocad.ru
Russian Federation, St. Petersburg, 198515
M. V. Petrova
BIOCAD Biotechnological Company, poselok Strel’na
Author for correspondence.
Email: petrovamv@biocad.ru
Russian Federation, St. Petersburg, 198515